Antitumour responses induced by a cell-based Reovirus vaccine in murine lung and melanoma models

Show simple item record

dc.contributor.author Campion, Ciorsdan A.
dc.contributor.author Soden, Declan
dc.contributor.author Forde, Patrick F.
dc.date.accessioned 2017-06-21T11:01:24Z
dc.date.available 2017-06-21T11:01:24Z
dc.date.issued 2016-07-13
dc.identifier.citation Campion, C. A., Soden, D. and Forde, P. F. (2016) 'Antitumour responses induced by a cell-based Reovirus vaccine in murine lung and melanoma models', BMC Cancer, 16, 46 (10pp).doi: 10.1186/s12885-016-2536-2 en
dc.identifier.volume 16
dc.identifier.startpage 1
dc.identifier.endpage 10
dc.identifier.issn 1471-2407
dc.identifier.uri http://hdl.handle.net/10468/4124
dc.identifier.doi 10.1186/s12885-016-2536-2
dc.description.abstract Background: The ever increasing knowledge in the areas of cell biology, the immune system and the mechanisms of cancer are allowing a new phase of immunotherapy to develop. The aim of cancer vaccination is to activate the host immune system and some success has been observed particularly in the use of the BCG vaccine for bladder cancer as an immunostimulant. Reovirus, an orphan virus, has proven itself as an oncolytic virus in vitro and in vivo. Over 80 % of tumour cell lines have been found to be susceptible to Reovirus infection and it is currently in phase III clinical trials. It has been shown to induce immune responses to tumours with very low toxicities. Methods: In this study, Reovirus was examined in two main approaches in vivo, in mice, using the melanoma B16F10 and Lewis Lung Carcinoma (LLC) models. Initially, mice were treated intratumourally (IT) with Reovirus and the immune responses determined by cytokine analysis. Mice were also vaccinated using a cell-based Reovirus vaccine and subsequently exposed to a tumourigenic dose of cells (B16F10 or LLC). Using the same cell-based Reovirus vaccine, established tumours were treated and subsequent immune responses and virus retrieval investigated. Results: Upregulation of several cytokines was observed following treatment and replication-competent virus was also retrieved from treated tumours. Varying levels of cytokine upregulation were observed and no replication-competent virus was retrieved in vaccine-treated mice. Prolongation of survival and delayed tumour growth were observed in all models and an immune response to Reovirus, either using Reovirus alone or a cell-based vaccine was also observed in all mice. Conclusion: This study provides evidence of immune response to tumours using a cell-based Reovirus vaccine in both tumour models investigated, B16F10 and LLC, cytokine induction was observed with prolongation of survival in almost all cases which may suggest a new method for using Reovirus in the clinic. en
dc.description.sponsorship Breakthrough Cancer Research/Cork Cancer Research Centre (CHY19801). en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher BioMed Central en
dc.relation.uri https://bmccancer.biomedcentral.com/articles/10.1186/s12885-016-2536-2
dc.rights © 2016, the Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. en
dc.rights.uri http://creativecommons.org/licenses/by/4.0/ en
dc.subject Reovirus en
dc.subject Immune en
dc.subject Cytokine en
dc.subject Cancer en
dc.subject Vaccine en
dc.title Antitumour responses induced by a cell-based Reovirus vaccine in murine lung and melanoma models en
dc.type Article (peer-reviewed) en
dc.internal.authorcontactother Ciorsdan A. Campion, Cork Cancer Research Centre, University College Cork, Cork, Ireland. +353-21-490-3000 Email: ciorsdan.campion@ucc.ie en
dc.internal.availability Full text available en
dc.description.version Published Version en
dc.contributor.funder Breakthrough Cancer Research, Ireland
dc.contributor.funder Cork Cancer Research Centre
dc.description.status Peer reviewed en
dc.identifier.journaltitle BMC Cancer en
dc.internal.IRISemailaddress ciorsdan.campion@ucc.ie en
dc.identifier.articleid 462


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2016, the Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Except where otherwise noted, this item's license is described as © 2016, the Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement